Autologous Serum Tears in the Management of Ocular Surface Diseases: A Comprehensive Review of Published Evidence.

IF 1.9 4区医学 Q2 OPHTHALMOLOGY

Seminars in Ophthalmology Pub Date : 2025-06-14 DOI:10.1080/08820538.2025.2519049

Konstantina Bachtalia, Athina Plakitsi, Sotiria Palioura

{"title":"Autologous Serum Tears in the Management of Ocular Surface Diseases: A Comprehensive Review of Published Evidence.","authors":"Konstantina Bachtalia, Athina Plakitsi, Sotiria Palioura","doi":"10.1080/08820538.2025.2519049","DOIUrl":null,"url":null,"abstract":"Purpose: This comprehensive review evaluates the efficacy and safety of autologous serum (AS) tears in managing dry eye disease (DED) by analyzing published prospective randomized controlled trials (RCTs).Methods: A comprehensive literature search was conducted in PubMed, Scopus, and the Cochrane Library up to February 28, 2025. The primary outcome measures included symptom improvement, Schirmer's test, tear break-up time, ocular surface staining, and visual performance. The Cochrane Risk of Bias Version 2 tool was used to assess study quality.Results: Six RCTs (102 participants, 169 eyes) were included. Significant symptom improvement was recorded with AS tears 20%. The most consistent improvement in clinical signs was observed with AS tears 50%. The risk of bias assessment identified only one study as high risk due to lack of blinding.Conclusion: AS tears show promise for moderate-to-severe DED, but variability in study design and small sample sizes necessitate standardized protocols and larger RCTs.","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-7"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08820538.2025.2519049","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This comprehensive review evaluates the efficacy and safety of autologous serum (AS) tears in managing dry eye disease (DED) by analyzing published prospective randomized controlled trials (RCTs).

Methods: A comprehensive literature search was conducted in PubMed, Scopus, and the Cochrane Library up to February 28, 2025. The primary outcome measures included symptom improvement, Schirmer's test, tear break-up time, ocular surface staining, and visual performance. The Cochrane Risk of Bias Version 2 tool was used to assess study quality.

Results: Six RCTs (102 participants, 169 eyes) were included. Significant symptom improvement was recorded with AS tears 20%. The most consistent improvement in clinical signs was observed with AS tears 50%. The risk of bias assessment identified only one study as high risk due to lack of blinding.

Conclusion: AS tears show promise for moderate-to-severe DED, but variability in study design and small sample sizes necessitate standardized protocols and larger RCTs.

查看原文本刊更多论文

自体血清泪液在眼表疾病治疗中的应用：已发表证据的综合综述

目的：本综述通过分析已发表的前瞻性随机对照试验（rct），评价自体血清（AS）泪液治疗干眼病（DED）的疗效和安全性。方法：综合检索PubMed、Scopus和Cochrane图书馆截至2025年2月28日的文献。主要结局指标包括症状改善、Schirmer试验、泪液破裂时间、眼表染色和视觉表现。使用Cochrane风险偏倚第2版工具评估研究质量。结果：纳入6项随机对照试验（102名受试者，169只眼睛）。有明显症状改善的AS泪20%记录。临床症状改善最一致的是50%的AS泪。由于缺乏盲法，偏倚风险评估只确定了一项研究为高风险。结论：AS泪液有望治疗中度至重度DED，但研究设计的可变性和小样本量需要标准化的方案和更大的随机对照试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in Ophthalmology OPHTHALMOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Seminars in Ophthalmology offers current, clinically oriented reviews on the diagnosis and treatment of ophthalmic disorders. Each issue focuses on a single topic, with a primary emphasis on appropriate surgical techniques.